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Abstract: Preparation of poly (ethylene glycol) (PEG)-grafted chitosan is essential for 
improving the biocompatibility and water solubility of chitosan. Presently available   methods 
for this have limitations. This article describes a new method for preparing PEGylated   chitosan 
nanoparticles. For this chitosan was chemoselectively modified using a novel scheme at the 
C6 position of its repeating units by PEG. The amine groups at the C2 position of the chitosan 
were protected using phthalic anhydride. Sodium hydride was used to catalyze the   etherification 
reaction between chlorinated chitosan and methyl-PEG, and PEG-grafted chitosan was 
successfully synthesized. Each step was characterized using 13C nuclear magnetic resonance 
and Fourier transform infrared. After PEGylation the phthaloylated chitosan was successfully 
deprotected using hydrazine monohydrate. The synthetic scheme proposed demonstrates a new 
method for grafting PEG onto chitosan with a moderate degree of substitution. The potential of 
this polymer in nanoparticle preparation using an ionic gelation method and its gene delivery 
potentials were investigated by complexing a fluorescently labeled control siRNA. The result 
showed that suitable nanoparticles can be synthesized using this polymer and that they have 
capacity to carry genes and provide adequate transfection efficacy with no toxicity when tested 
in neuronal cells.
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Introduction
Chitosan is a linear polymer composed of β-(1–4)-2-amino-2-deoxy-D-glucopyranose 
units. Being a polycationic, nontoxic, biodegradable, and biocompatible polymer, 
chitosan has attracted much attention and has wide applications in biotechnology, 
  pharmaceutical, textile, food, cosmetics, and agricultural industries.1,2 Current research 
with chitosan focuses on its use as a novel drug, gene, peptide, and vaccine delivery 
vehicle, and scaffold for targeted delivery and tissue engineering applications.3–6 
Chitosan has achieved much interest compared with chitin and cellulose due to the 
presence of primary amine groups present in its repeating units. The presence of primary 
amine groups makes chitosan an excellent cell transfectant. Like polyethyleneimine, 
chitosan exhibits a “proton sponge” effect, which refers to the swelling behavior 
of the polymer on encountering an acidic pH inside the cell’s endosome, making 
it an efficient carrier for therapeutic molecules.7–9 A number of chitosan derivatives 
have been synthesized in the past with modification on the primary amine groups of the 
polymer.10,11 Chitosan is soluble only in acidic aqueous solutions due to the   presence 
of amine groups that become protonated, and thus its poor solubility in other organic 
solvents has become a major drawback, limiting its effective utilization.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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To facilitate the effective use of chitosan in gene   delivery 
and other biomedical applications, it is necessary to make 
chitosan soluble either in water or organic solvents. Such 
attempts can be made by graft copolymerization of   chitosan 
through chemical modifications with other polymers, such 
as poly (ethylene glycol) (PEG), of different molecular 
weights.12 This allows chitosan to retain its inherent 
characteristics of, for example, molecular structure and 
length, and allows for a variety of chemical modifications or 
reactions on its side chain. However, chemical modification 
at amine groups leads to a change in the fundamental skele-
ton of chitosan, causing it to lose its original physiochemical 
and biochemical activities.12 Recently, modifying hydroxyl 
groups of chitosan has gained much importance as it does 
not influence the characteristic structural and functional 
features of chitosan.
PEG is widely used as a graft-forming polymer. It is 
soluble in both water and organic solvents, has no toxicity, 
antigenicity, and immunogenicity, and is biodegradable and 
biocompatible.13 PEGylation of chitosan through hydroxyl 
groups was first proposed by Gorochovceva and Makuska.14 
PEG has been used mainly as a graft polymer, where it is used 
as a crosslinker and forms interconnected channels to enable 
drug release.15,16 Various preparation techniques can be used 
to prepare chitosan nanocarriers by altering parameters 
such as concentration of the polymer or the crosslinker, the 
molecular weight of chitosan, the ratio of drug/gene:polymer, 
pH, and finally stabilizers or surfactants. All these factors 
collectively affect the structural and morphological properties 
of chitosan nanoparticles and the release rate of the loaded 
therapeutic molecule.17
This study aims to achieve facile chemoselective con-
jugation of PEG at the hydroxyl group of chitosan, where 
the amine groups of chitosan were first protected using 
phthalic anhydride.18 Nanoparticles were formed using an 
ionic gelation method. The concentration of the polymer 
versus crosslinker and the pH of the solution were adjusted 
with reference to our previously optimized study.19 The 
current study opens up the future application of forming 
PEG-grafted chitosan nanoparticles for efficient gene/drug 
delivery.
Materials and methods
Materials
Low-molecular-weight chitosan was obtained from Wako 
(Richmond, VA, USA), having a viscosity of 5–20 cP and 
a degree of deacetylation of 80.0%. Poly (ethylene glycol) 
monomethyl ether (MW 5000), phthalic anhydride, sodium 
hydride (NaH), pyridine, hydrazine monohydrate, sodium 
tripolyphosphate (TPP), glacial acetic acid, agarose (low 
gelling temperature), and ethidium bromide (10 mg/mL) 
of   analytical grade were obtained from Sigma-Aldrich 
(Oakville, ON, Canada). Anhydrous tetrahydrofuran 
(THF), anhydrous N,N-dimethylformamide (DMF), sodium 
hydroxide (NaOH) and methanol were obtained from 
Thermo Fisher Scientific (Ottawa, ON, Canada). Thionyl 
chloride (SOCl2) was obtained from VWR (Mississauga, 
ON, Canada). For dilution purposes, ultra pure double-
distilled water (ddH2O) was used from a laboratory-installed 
Barnstead Nanopure   diamond™ water supply unit. siGLO 
(Green) transfection indicator (20 nmole) was obtained 
from Dharmacon (Lafayette, IN, USA). CellTiter 96® 
AQueous One Solution Reagent was purchased from Pro-
mega (Madison, WI, USA) to perform cell viability assay. 
TrackIt 10 bp DNA ladder (0.5 µg/µL) was obtained from 
Invitrogen (Burlington, ON, Canada). Neuro2a cell line 
and Eagle’s minimum essential medium (EMEM) were 
obtained from Cedarlane (Burlington, ON, Canada) and 
supplemented with 10% fetal bovine serum (FBS) from 
Invitrogen (Burlington, ON, Canada).
Deacetylation of chitosan
Commercially available low-molecular-weight chitosan (5 g) 
was added to a 40% (w/v) aqueous NaOH solution. The 
mixture was stirred for 4 hours at 110°C under a nitrogen 
atmosphere. After 4 hours the mixture was vacuum filtered, 
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Figure 1 schematic of O-Pegylated chitosan polymer preparation using Nah and 
ThF: A) chitosan; B) deacetylated chitosan; C) phthaloyl chitosan; D) chlorinated 
phthaloyl chitosan intermediate; E) Pegylated phthaloyl chitosan; and F) Pegylated 
chitosan.
Abbreviations: Nah, sodium hydride; ThF, tetrahydrofuran.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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pulverized, and was again treated with 40% (w/v) NaOH 
under similar conditions. The resultant product (b) in Figure 1 
was freeze-dried.20
Phthaloylation of chitosan
Deacetylated chitosan (1.00 g) was added to a solution of 
phthalic anhydride (2.76 g) in 20 mL of DMF. The mixture 
was stirred for 8 hours at 120°C under a nitrogen atmosphere. 
The resultant product (c) in Figure 1 was cooled to room 
temperature and precipitated in ice cold water. The precipitate 
was filtered, washed with methanol overnight, and vacuum 
dried.18,21
synthesis of Pegylated chitosan 
(chitosan-O-Peg)
We employed a novel scheme to PEGylate chitosan chemose-
lectively. The scheme depicted in Figure 1   utilizes the 
activation of PEG by NaH, used as a catalyst to   conjugate 
PEG and chitosan. The synthesis was accomplished in 3 steps: 
1) chlorination of chitosan, 2) activation of   OH-PEG-OCH3 
(mPEG) with NaH, and 3) grafting activated mPEG onto 
chlorinated chitosan. To prepare chlorinated chitosan, SOCl2 
was added in 10-fold excess compared to phthaloylated 
chitosan (0.1 g) in 20 mL of pyridine. The reaction was stirred 
at 80°C for 30 minutes under a nitrogen atmosphere. After 
30 minutes, the reaction was cooled to room temperature, 
precipitated in ice cold water, filtered, and vacuum dried to 
yield chlorinated-phthaloyl chitosan, product (d) in Figure 1. 
PEG was activated by adding 4 g of OH-PEG-OCH3 (mPEG) 
to a suspension of NaH (10 mg) in 50 mL of anhydrous THF. 
The reaction was stirred at 60°C for 2 hours under nitrogen 
atmosphere. After 2 hours, chlorinated-phthaloyl chitosan 
(60 mg) was added to the reaction mix and stirred for another 
16 hours under similar conditions. After 16 hours the reaction 
was allowed to cool at room temperature and was precipitated 
in methanol, filtered, and vacuum dried to yield product (e) 
in Figure 1.
Deprotection of Pegylated-phthaloyl 
chitosan
PEGylated-phthaloyl chitosan (100 mg), hydrazine mono-
hydrate (15 mL), and distilled water (30 mL) were mixed 
and heated at 100°C for 16 hours under constant magnetic 
stirring. Excess hydrazine monohydrate was removed by 
evaporating the mixture using a rotary evaporator until a 
viscous solution was left. The process was repeated 3 times 
by reconstituting the mix with distilled water each time and 
then rotary evaporating it until a solid residue was left. The 
final product was dried under vacuum to obtain the desired 
PEGylated chitosan.
Preparation of Pegylated chitosan 
nanoparticles
PEGylated chitosan nanoparticles were prepared by an 
ionic gelation procedure, as explained in previous studies.22 
After the deprotection of PEGylated-phthaloyl chitosan, the 
polymer was dissolved in 1% (v/v) acetic acid   solution to yield 
a concentration of 0.5 mg/mL and the pH was adjusted to 5. 
TPP was dissolved in ddH2O to obtain a concentration of 
0.7 mg/mL and the pH was adjusted to 3.19 Nanoparticles were 
formed after the addition of TPP (  drop-wise) to the chitosan 
solution under constant magnetic stirring for 1 hour at room 
temperature. The nanoparticles obtained were   characterized 
by TEM for their morphology and size.
Gene loading efficiency by the gel 
retardation assay
The encapsulation/gene loading efficiency of PEGylated 
chitosan polymer was determined by complexing it with 
siGLO, a transfection indicator, to form nanoparticles 
  following similar conditions as described in section 2.6. 
The free siGLO in PBS and siGLO complexed with 
nanoparticles were run in duplicates on a 4% w/v agarose 
gel   electrophoresis for 4 hours at 55 V in Tris/Borate/EDTA 
(TBE)   buffer (pH 8.3). The siGLO complexation with nano-
particles was performed at a ratio of 200:1 (polymer:gene) 
(w/w), as   determined in our previous study.19 The TBE 
  buffer used contained ethidium bromide at a concentration 
of 0.5 µg/mL, which is required for the visualization of 
the RNA bands under UV transilluminator at a wavelength 
of 365 nm using a ChemiDoc™ XRS System (Bio-Rad,   
Hercules, CA).
Transfection efficiency and cell viability 
assay
Mouse neuroblastoma cells (Neuro2a) were seeded in 
a 96-well plate at a density of 20,000 cells per well in 
complete growth media (antibiotics-free EMEM with 
10% serum). The transfection study was performed after 
24 hours of initial seeding. The different tested samples 
were: chitosan–TPP nanoparticles and free siGLO as 
  controls, chitosan–TPP:siGLO nanoparticles, and PEGy-
lated chitosan–TPP:siGLO   nanoparticles (200:1 w/w) as 
treatment samples. The cells were then incubated at 37°C, 
5% CO2 for 4 hours, after which the cells were observed 
under   fluorescence microscope (Nikon Eclipse TE2000-U) International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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at a wavelength of 490 nm. The same treatment and control 
samples were also used for a cytotoxicity assay. The 
  cytotoxicity assay was performed after 4 hours using Cell-
Titer 96® AQueous One Solution Reagent (MTS assay), as 
per manufacturer’s protocol. After an additional incubation 
of 4 hours with the MTS assay the absorbance in each well 
was recorded at 490 nm using a microtiter plate reader (Perkin 
Elmer® 1420 Multilabel Counter Victor 3TM V). The cell 
study was performed in triplicate.
statistical analysis
Values are expressed as means ± standard deviations (SD). 
The statistical significance was determined by using an 
independent t-test to compare the values of chitosan-TPP 
nanoparticles with PEGylated chitosan–TPP nanopar-
ticles (n = 3 for each group). P values of ,0.05 were 
considered significant. Statistical analysis was carried 
out using Minitab (Minitab, Version 14; Minitab Inc, 
State College, PA).
Results
Deacetylation of chitosan
The 13C nuclear magnetic resonance (NMR) of deacetylated 
chitosan confirmed the absence of an acetyl peak (-CH3) 
at 23.88 ppm and a carbonyl peak (-C=O) at 175.04 ppm 
present in the commercially available chitosan. NMR: 
(topological substructural molecular design (TOSS mode) 
of commercially available chitosan: δC 23.88 (CH3), 59.01 
(C-2), 61.76 (C-6), 75.64 (C-5, 3), 82.51 (C-4), 105.68 
(C-1), 175.04 (C=O). 13C CP/MAS NMR: (TOSS mode) of 
deacetylated chitosan: δC 60.76 (C-2, 6), 75.84 (C-4, 5, 3), 
102.80 (C-1).
Phthaloylation of chitosan
The  13C NMR in TOSS mode of phthaloylated chitosan 
confirmed the appearance of peaks Phth phenylene and Phth 
C=O at 134.42 ppm and 169.66 ppm, respectively, and the 
appearance of Phth C-1,2 and Phth C=O peaks at 131.63 
ppm and 169.89 ppm, respectively, in TOSDL mode. 
13C CP/MAS NMR: (TOSS mode): δC 58.19 (C-2), 61.76 
(C-6), 72.44 (C-3), 75.42 (C-5), 83.91 (C-4), 101.24 (C-1), 
124.62, 131.70, 134.42 (Phth phenylene), and 169.66 
(Phth C=O); (TOSDL mode): δC 131.63 (Phth C-1,2) and 
169.89 (Phth C=O). Fourier transform infrared (FTIR) of 
phthaloylated chitosan as represented in Figure 2b: νmax/cm-1 
3200–3400 (OH), 1774 (imide C=O), 1710 (imide C=O), 
1150–1000 (pyranose), and 720 (arom). FTIR of commercially 
available chitosan as shown in Figure 2a: νmax/cm-1 1630 
(amide I), 1542 (amide II), and 1024 (pyranose).
synthesis of Pegylated chitosan
The FTIR spectra presented in Figure 2d represent PEGylated 
chitosan with the characteristic peaks at νmax/cm-1: 2871 (C-H 
stretching), 1066 (C-O stretching), 1290, 1251, 950 and 
837, confirming the PEG5000 substitution when compared to 
Figure 2c that represents the FTIR spectra of PEG only with 
the characteristic peaks at νmax/cm-1: 2878 (C-H stretching), 
1100 (C-O stretching), 1466, and 1278.
Deprotection of Pegylated-phthaloyl 
chitosan
The FTIR spectra presented in Figure 2e represent depro-
tected PEGylated chitosan with the characteristic peaks at 
νmax/cm-1: 2878 (C-H stretching), 1066 (C-O stretching) 
belonging to PEG, the appearance of 1633 (amide I), 1582 
(amide II), and 1024 (pyranose) belonging to chitosan, and 
the disappearance of 1774 (imide C=O), 1710 (imide C=O) 
belonging to the phthaloyl group, as shown in Figure 2b.
Preparation of Pegylated chitosan 
nanoparticles
Deprotected PEGylated chitosan polymer was cross-
linked with TPP by the electrostatic interaction between 
the   cationic charges of the primary amine groups on 
  chitosan with the anionic charges of TPP. The crosslink-
ing results in the   formation of nanoparticles ranging from 
100 to 150 nm in size as determined by transmission 
electron microscopy (TEM). Figure 3a represents the 
TEM image of the   PEGylated   chitosan polymer (magni-
fication: 57000X). Figure 3b   represents the chitosan–TPP 
  nanoparticles (  magnification: 22000X) and   Figure 3c and 
3d represents the PEGylated chitosan-TPP nanoparticles 
at magnification 57000X and 135000X respectively. It was 
observed that PEGylation yielded a spherical shape to the 
nanoparticles.
Gene loading efficiency of PEGylated 
chitosan nanoparticles
In order to evaluate the complexation of siGLO with 
PEGylated chitosan-TPP nanoparticles, a gel retardation 
assay was performed, wherein a 10 bp DNA ladder was used 
as a reference, free siGLO at a concentration of 6 µg/mL 
of PBS solution was used as the control and PEGylated 
chitosan–TPP nanoparticles complexing siGLO at a ratio 
of 200:1 (w/w), as determined in our previous study, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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was used as the treatment sample.19 The gel, under a UV 
transilluminator, shows bands indicating the presence of 
unbound siGLO in the suspension, as shown in Figure 4, 
for the control sample (ie, free siGLO in PBS), whereas 
there is no band in a treatment sample, which confirms 
the complete complexation of the siGLO with PEGylated 
chitosan nanoparticles. The strong interaction pertains to 
the positive charges available on the chitosan chain after 
the deprotection procedure on the polymer allowing the 
interaction with the negatively charged siGLO and TPP.
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Figure 2 Fourier transform infrared spectra of the chitosan intermediates and O-Pegylated chitosan: A) deacetylated chitosan; B) phthaloylated chitosan: peaks at 
1774 cm-1and 1702 cm-1. The Oh groups of phthaloylated chitosan was chlorinated using thionyl chloride, represented by the reduction in peak: from 3500 to 3200 cm-1; 
C) Oh-Peg-Och3, M.W. 5,000; D) 6-O-Peg-g-2-N-phthaloyl chitosan; E) Peg-grafted chitosan: disappearance of peaks 1774 cm-1 and 1702 cm-1.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 TeM images of a) Pegylated chitosan polymer (mag. 57,000×); b) chitosan– 
TPP  nanoparticle  (mag.  22,000×);  c)  Pegylated  chitosan–TPP  nanoparticle 
(mag. 57,000×) and d), Pegy lated chitosan-TPP nanoparticle (mag. 135000x).
Abbreviation: TPP, sodium tripolyphosphate.
330
100
40
20
10
10 bp
DNA
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Free siGLO
Pegylatedchitosan
with siGLO
Figure 4 gel retardation assay: lane 1) control 10 bp DNA ladder; lane 2 and 3 
control sigLO, and lane 4 and 5 are Pegylated chitosan complexed sigLO at a ratio 
of 200:1 (w/w). In all groups the sigLO concentration was kept constant at 6 µg/mL. 
The disappearance of the band size at 40 bp in Pegylated chitosan complexed sigLO 
(lanes 4 and 5), compared to siglO control (lanes 2 and 3), indicates the complete 
complexation of the sigLO. Transfection efficiency and cell viability 
assay
The transfection efficiency was analyzed by measuring the 
fluorescence intensity of the siGLO-loaded nanoparticles. 
siGLO is a transfection indicator, which is a fluorescent 
oligonucleotide that is localized in the nucleus of the 
  mammalian cell (Figure 5). Free siGLO, chitosan–TPP 
nanoparticles, and cells without any treatment sample were 
used as negative controls. An efficient transfection effi-
ciency was observed with both chitosan–TPP:siGLO and 
PEGylated chitosan–TPP:siGLO nanoparticles prepared 
at a weight ratio of 200:1 (Figure 5). The cell viability 
assay was performed on these cells after 4 hours, wherein 
it was observed that cells treated with PEGylated chitosan–
TPP:siGLO nanoparticles showed significant increase in cell 
viability (≈70%)   compared with the chitosan–TPP:siGLO 
nanoparticles (≈20%) (  independent t-test, P , 0.05), as 
observed in Figure 6.
Discussion
The degree of N-acetylation of chitin differentiates it from 
chitosan. The lower degree of N-acetylation of chitosan 
widens its application for chemical modifications with the 
amine groups, imparts greater solubility to the polymer, and 
enhances its biological properties. Unlike chitin, chitosan is 
soluble only in acidic aqueous solutions. The solubility of 
the polymer is an important parameter for having a homoge-
neous reaction mixture in order to obtain successful chemical 
modifications. The solubility of chitosan also depends on 
its molecular weight, its degree of neutralization of amine 
groups, the ionic strength of the solvent, and the distribution 
of N-acetyl glucosamine residues along the backbone of 
the chain.23 In these experiments complete deacetylation of 
chitosan was achieved after treating it twice with a 40% (w/v) 
NaOH solution. Products (a) and (b) in Figure 1 represent 
the schematic of acetylated chitosan (commercially available) 
and deacetylated chitosan, respectively.
The complete deacetylation is required to achieve a chi-
tosan with fully activated amine groups allowing for fur-
ther chemical reactions but renders crystalline character to 
the polymer, making it insoluble in most organic solvents.21 
In order to solubilize chitosan in organic solvents and to 
avoid the interference of amine groups while performing 
chemical modifications on the backbone, the amine groups 
of chitosan were protected using phthalic anhydride.21 
Since it has been observed that phthaloylation of chito-
san in 100% DMF yields partial O-phthaloylation along 
with N-phthaloylation, we attempted to use DMF/water International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and 169.89 ppm assigned to C 1, 2 and carbonyl of phthaloyl 
group, respectively. The IR data show distinct sharp peaks at 
1774 cm-1 and 1702 cm-1 corresponding to imide of phthaloyl 
group (Figure 2b). The phthaloyl chitosan prepared by this 
method becomes gel-like when precipitated in water, which 
supports the data shown by Kurita et al of formation of a 
uniform structure of phthaloylated chitosan.21
The 2-N-phthaloylated chitosan formed was further 
reacted with thionyl chloride to obtain chlorinated chitosan 
as represented by product (d) in Figure 1. The IR data in 
  Figure 2b show the disappearance of the OH peak in the range 
of 3200 cm-1 to 3400 cm-1 in chlorinated phthaloyl chitosan, 
confirming the replacement of hydroxyl groups with chlorine 
and the peaks pertaining to imide bond of phthaloyl group 
(1774 cm-1 and 1710 cm-1) remain intact.
Simultaneously, mPEG (OH-PEG-OCH3) was activated by 
NaH in THF to form PEG alkoxide (-O-PEG-OCH3). To this 
intermediate, chlorinated phthaloyl chitosan was added to 
form PEG-grafted phthaloyl chitosan. The desired product was 
precipitated in methanol, with unreacted PEG being soluble 
in this solvent. This method is the most direct and the easi-
est way to obtain PEG-grafted chitosan and does not require 
any intensive purification procedures. Product (e) in Figure 1 
represents the schematic of PEGylated phthaloyl chitosan.
The deprotection of the chitosan was successfully 
achieved by treating the PEGylated phthaloyl chitosan, 
product (e) in Figure 1, with hydrazine monohydrate, which 
c) b)
) e ) d
a)
Figure 5 Transfection efficiency of nanoparticles on Neuro2a cells after 4 hours of incubation at 37°c and 5% cO2: a) Pegylated-chitosan-TPP:sigLO nanoparticles; b) 
chitosan-TPP:sigLO nanoparticles; c) sigLO only (negative control); d) chitosan-TPP nanoparticles (negative control); e) cells only (negative control) 
Abbreviation: TPP, sodium tripolyphosphate.
(95:5 v/v) as a solvent.21 However, it was observed that the 
product obtained did not solubilize homogeneously in most 
of the organic solvents, which in turn was a hindrance to 
perform further chemical reactions. Thus, in this chemical 
scheme we did not incorporate the use of DMF/water (95:5 
v/v) as a solvent to synthesize phthaloylated chitosan.
13C NMR data confirm the successful N-phthaloylation 
of the product. Product (c) in Figure 1 shows the schematic 
representation of the N-phthaloyl chitosan. The total sup-
pression of side bands (TOSS mode) exhibits peaks at 
124.62 ppm, 131.70 ppm, 134.42 ppm corresponding to 
phenylene, and 169.66 ppm and carbonyl group of phthaloyl 
group and the TOSS – dipolar dephasing (TOSDL) mode 
confirms the absence of CH and CH2 peaks due to their short 
relaxation time and presence of only 2 peaks 131.63 ppm 
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Figure 6 Designed cs-TPP-Peg-sigLO nanoparticle cytotoxicity was investigated 
using Neuro2a cells. For the experiment, various control nanoparticle formulations 
were used, the Neuro2a cells were exposed for 4 hours and cell viability was 
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causes destabilization of the phthaloyl moiety by creating an 
excess alkaline condition of pH . 12. Product (f) in Figure 1 
represents the final product achieved: PEG-grafted chitosan. 
The absence of peaks at 1774 cm-1 and 1710 cm-1 in   product 
(e) confirms the complete dissociation of   phthalimido group 
from chitosan and the appearance of peaks 1633 cm-1 
(amide I) and 1582 cm-1 (amide II) corresponds to the 
presence of primary amine groups in chitosan. The peak 
at 2871 cm-1 refers to the presence of PEG in product (e), 
Figure 1. The data on 1H NMR are not shown since it was 
observed that the multiple peaks of oxymethyl groups in 
PEG obtained at δ 3.3 to 3.7 cover over the signals of the 
pyranose ring of chitosan.
The reaction conditions used in the scheme for O-PE-
Gylating chitosan are less intensive in terms of operation 
and purification. However, NaH, used as a catalyst, makes 
the reaction conditions alkaline which can potentially have a 
deleterious effect on the phthaloyl group of chitosan. But, a 
correct proportion of NaH, PEG, and chitosan can optimize 
the reaction conditions. In our study we used 2:4:1 molar 
ratio of NaH:PEG:chitosan. The studies conducted by 
Makuska’s group used Ag2O as a catalyst, producing less 
alkalinity in the solution, suitable for the etherification 
reaction between chitosan and PEG. The reaction yielded a 
high degree of   substitution of PEG on chitosan, but as stated 
by the researchers, the residual silver salts that remain in 
the reaction lead to degradation of chitosan polymer while 
undergoing deprotection with hydrazine.24 Also, the overall 
yield of the PEGylated chitosan was less and involved 28 to 
30 hours of reaction time. Even after implementing several 
cycles of purification on PEGylated chitosan intermediate, 
it could not completely remove the silver particles. Thus, 
the procedure involves intensive and multiple steps to obtain 
the desired product. The use of NaH as a catalyst is more 
promising than using Ag2O as a catalyst. In our case, the 
degree of substitution of PEG on chitosan can be increased 
by using low molecular weight PEG, but not ,1000 due 
to the high solubility of PEG in aqueous as well as organic 
  solvents. We also tried PEGylating chitosan through a scheme 
followed by Jian and You-Lo, in which phthaloylated chitosan 
was first swelled in pyridine overnight.25 Other researchers 
have used NaOH to swell chitosan prior to the reaction 
in order to achieve homogeneous conditions. NaOH can 
deprotect the phthaloyl group on chitosan, and therefore its 
use was avoided and using pyridine as a solvent was favored 
due to the solubility of phthaloylated chitosan in pyridine. 
We obtained similar results in terms of yield of PEGylated 
chitosan by following the protocol of Jian and You-Lo with 
the exception of the use of PEG acyl chloride followed by 
multiple steps that take more time (36–40 hours) in terms 
of reaction and purification at each step to obtain the final 
product. The total reaction time employed in this scheme, 
using NaH, was 18 to 20 hours.
The proposed scheme yielded a moderate (15%–50%) 
degree of substitution of PEG on chitosan, which was 
soluble in acetone, toluene, chloroform, DMF, and ethyl 
acetate at 50°C. Also, as reported earlier, O-PEGylated 
chitosans with free amino groups have a wider application 
in biotechnology and biomedical systems because of the 
unchanged poly (glucosamine) skeleton.14 As PEG separates 
the chitosan backbone, thereby decreasing intermolecular 
hydrogen bonding and making it water soluble, it acts as 
an important intermediate to carry out further chemical 
modifications.
Chitosan nanoparticles were prepared by ionic gelation 
that involves a mixture of 2 aqueous phases, of which one 
is the polymer chitosan and the other is a polyanion TPP. 
The positively charged amino group of chitosan interacts 
with negatively charged TPP to form complex coacervates 
with a size of about 100 nm.26–27 The nanoparticles formed 
can have a significant application as a drug/gene carrier 
system for biomedical applications both in vitro and in 
vivo. In this study, we have complexed siGLO, a scrambled 
siRNA with a fluorescent tag with the nanoparticles prepared 
from the proposed formulation of PEGylated chitosan poly-
mer. Complete complexation of the siGLO was achieved 
as confirmed by the gel retardation study. The optimal 
concentration of siGLO to be used for complexation was 
initially   determined by our group and has been published 
previously as a characterization study.19 The PEGylated 
chitosan polymer complexing siGLO was used as a nanocar-
rier to transfect a neuronal cell line in order to determine 
the transfection efficiency of the nanoparticle/carrier. It has 
been reported by many researchers that PEGylation reduces 
the   transfection efficiency of the nanoparticles since PEG, 
being neutral in charge, does not efficiently interact with 
the negatively charged cell membrane. However, in this 
study, the facile chemoselective substitution of PEG on the 
C6 position was favored, especially so as not to affect the 
primary amine groups on chitosan that play a major role is 
gene   complexation and cell transfection.
The transfection study, as shown in Figure 5, confirmed 
the efficient uptake of PEGylated chitosan nanoparticles (a) 
compared with chitosan nanoparticles alone (b). This proves 
that conjugating PEG on the C6 position of the chitosan 
polymer did not hinder the inherent character of the chitosan International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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polymer to complex and to deliver the siGLO to neuronal 
cells. To further investigate the effect of nanoparticles on the 
cells, a cell viability assay was performed. This confirmed the 
stressed conditions of cells transfected with chitosan nano-
particles alone. The results indicated that although primary 
amine groups contribute significantly to transfection they 
may also disrupt the cellular integrity of the cell membrane 
due to an excessive positive charge on the nanoparticles. 
The presence of PEG on the nanoparticles reduces steric 
hindrance and makes nanoparticles more hydrophilic. Also, 
as observed in Figure 6, the cytotoxicity was greater for the 
chitosan nanoparticles complexing siGLO than the chitosan 
nanparticles alone. This could be inferred from a reduction 
in size of the nanoparticles after complexing siGLO, which 
in turn allows more particle interaction with the cell mem-
brane, thereby increasing the surface area. The optimization 
study based on the particle size and zeta potential of chitosan 
nanoparticles with and without siGLO has previously been 
published by our group.19
Conclusion
We achieved successful grafting of PEG on chitosan poly-
mer through a novel scheme of forming PEG alkoxide using 
NaH as a catalyst. The PEGylated chitosan polymer obtained 
was easily soluble in water and other organic solvents. The 
overall procedure is easier and requires less intensive reac-
tion conditions and purification steps to obtain the desired 
product in a short period of time than the other methods 
used by other protocols reported in the literature. Also, the 
procedure does not impart any deleterious effect on the 
chitosan chain. The PEGylated chitosan nanoparticles suc-
cessfully complexed siRNA and transfected into the neuronal 
cell line with minimal cytotoxicity effects. The proposed 
formulation could have a major implication for biomedical 
drug targeting strategies involving nanoparticle-mediated 
targeted delivery.
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